利用遗传学评估常用降压药与糖尿病、血糖性状及血脂的关联:一项跨 ancestry 孟德尔随机化研究
研究采用跨 ancestry 孟德尔随机化方法,评估 ACE 抑制剂、β 受体阻滞剂和钙通道阻滞剂的遗传代理与糖尿病、血糖及血脂的关联。结果显示,ACE 抑制遗传代理与糖尿病风险降低相关(OR 0.85,95%CI 0.78-0.93),β 受体阻滞剂遗传代理与糖尿病风险升高相关(OR 1.05,95%CI 1.02-1.09),后两者及钙通道阻滞剂还与不利血脂谱相关。
要点
- ACE 抑制遗传代理与糖尿病风险降低相关(OR 0.85,95%CI 0.78-0.93)。
- β 受体阻滞剂遗传代理与糖尿病风险升高相关(OR 1.05,95%CI 1.02-1.09)。
- β 受体阻滞剂遗传代理与 HDL 胆固醇降低及甘油三酯升高相关,钙通道阻滞剂遗传代理与 LDL 胆固醇升高相关。
核心结论
- 遗传代理的 ACE 抑制与糖尿病呈保护性关联,而 β 受体阻滞剂和钙通道阻滞剂的遗传代理可能与不利的代谢谱相关。
研究设计与样本
- 采用孟德尔随机化方法,使用欧洲和东亚人群中药物靶基因及与收缩压相关的遗传变异,评估 ACE 抑制剂、β 受体阻滞剂和钙通道阻滞剂的遗传代理与糖尿病、血糖、HbA1c 及血脂的关联。
- 糖尿病遗传关联数据来自欧洲人群 74,124 例病例和 824,006 例对照,东亚人群 77,418 例病例和 356,122 例对照。
- 血糖及血脂遗传关联数据来自约 50 万欧洲人和 10 万东亚人。
- 以冠状动脉疾病作为对照结局,并使用不同的遗传工具和分析方法进行敏感性分析。
主要发现
- 遗传代理的 ACE 抑制、β 受体阻滞剂和钙通道阻滞剂在两个 ancestry 中均与冠状动脉疾病风险降低相关。
- 遗传代理的 ACE 抑制与糖尿病风险降低相关(OR 0.85,95%CI 0.78-0.93)。
- β 受体阻滞剂遗传代理与糖尿病风险升高相关(OR 1.05,95%CI 1.02-1.09)。
- 在东亚人群中估计值相似,并得到随机对照试验的系统综述和 meta 分析的佐证。
- 在两个 ancestry 中,β 受体阻滞剂遗传代理与 HDL 胆固醇降低及甘油三酯升高相关,钙通道阻滞剂遗传代理与 LDL 胆固醇升高相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetes and hyperlipidaemia are common comorbidities in people with hypertension. Despite similar protective effects on CVD, different classes of antihypertensive drugs have different effects on CVD risk factors, including diabetes, glucose metabolism and lipids. However, these pleiotropic effects have not been assessed in long-term, large randomised controlled trials, especially for East Asians. METHODS: We used Mendelian randomisation to obtain unconfounded associations of ACE inhibitors, β-blockers (BBs) and calcium channel blockers (CCBs). Specifically, we used genetic variants in drug target genes and related to systolic BP in Europeans and East Asians, and applied them to the largest available genome-wide association studies of diabetes (74,124 cases and 824,006 controls in Europeans, 77,418 cases and 356,122 controls in East Asians), blood glucose levels, HbA1c, and lipids (LDL-cholesterol, HDL-cholesterol and triacylglycerols) (approximately 0.5 million Europeans and 0.1 million East Asians). We used coronary artery disease (CAD) as a control outcome and used different genetic instruments and analysis methods as sensitivity analyses. RESULTS: As expected, genetically proxied ACE inhibition, BBs and CCBs were related to lower risk of CAD in both ancestries. Genetically proxied ACE inhibition was associated with a lower risk of diabetes (OR 0.85, 95% CI 0.78-0.93), and genetic proxies for BBs were associated with a higher risk of diabetes (OR 1.05, 95% CI 1.02-1.09). The estimates were similar in East Asians, and were corroborated by systematic review and meta-analyses of randomised controlled trials. In both ancestries, genetic proxies for BBs were associated with lower HDL-cholesterol and higher triacylglycerols, and genetic proxies for CCBs were associated with higher LDL-cholesterol. The estimates were robust to the use of different genetic instruments and analytical methods. CONCLUSIONS/INTERPRETATION: Our findings suggest protective association of genetically proxied ACE inhibition with diabetes, while genetic proxies for BBs and CCBs possibly relate to an unfavourable metabolic profile. Developing a deeper understanding of the pathways underlying these diverse associations would be worthwhile, with implications for drug repositioning as well as optimal CVD prevention and treatment strategies in people with hypertension, diabetes and/or hyperlipidaemia.
引用
- Zhao JV, Liu F, Schooling CM, et al. Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation study. Diabetologia. 2022. PMID: 35080656. doi:10.1007/s00125-021-05645-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。